###begin article-title 0
Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy
###end article-title 0
###begin title 1
Purpose
###end title 1
###begin p 2
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human DNA topoisomerases I and II (topo-I and -II) are essential for vital cellular processes such as DNA replication, transcription, translation, recombination, and repair. In the present study, we correlate topo-I and -II expression and outcome after chemotherapy in primary and relapsed colorectal cancer.
###end p 2
###begin title 3
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods
###end title 3
###begin p 4
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 282 286 <span type="species:ncbi:162683">Mayo</span>
Patients with colorectal cancer that had recurred, following surgery and adjuvant chemotherapy and underwent a second operation were included in the present study. All had undergone surgical resection of the primary tumor and received post-operatively 5-FU-based (5FU + Leucovorin, Mayo Clinic regimen) adjuvant chemotherapy. Tumor tissue was collected at the initial operation from the primary tumor and at the time of recurrence (during the second operation following chemotherapy). All tissue samples were analyzed for levels of expression of both topo-I and topo-IIa using standard three-step immunohistochemistry on paraffin sections.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 155 157 155 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 280 282 280 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 304 306 304 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
###xml 245 253 <span type="species:ncbi:9606">patients</span>
Forty patients were included. Levels of expression of topo-I and topo-II were higher in malignant cells from tumor recurrences compared to primary tumors (P = 0.0001 for both). There was a statistically significant positive relationship between patients age and levels of topo-I (P = 0.011) and topo-II (P = 0.011) expression.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
The study results reported here underscore the role of topoisomerase expression in colorectal cancer and suggest a potential role in tumor recurrence.
###end p 8
###begin title 9
Keywords
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 169 177 <span type="species:ncbi:9606">patients</span>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
The aim of the present study was to investigate whether chemotherapy with 5-FU alters the levels of topoisomerase I (topo-I) and II (topo-II) in neoplastic tissues from patients with colorectal cancer. To this end, we examined the relationship between clinical data and the expression of topo I and II in patients treated with 5-FU post-operatively and who underwent surgery at recurrence.
###end p 11
###begin p 12
###xml 356 357 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 358 359 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 583 584 583 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 750 751 743 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 753 754 746 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 874 875 863 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 678 683 <span type="species:ncbi:9606">human</span>
Human DNA topo-I is an essential nuclear enzyme for vital cellular processes such as DNA replication, transcription, translation, recombination and repair. Topo-I unwinds and uncoils the supercoiled DNA double helix by transiently cleaving one of the two strands and allowing its rotation over the other, following which topo-I reseals the cleaved strand [1-5]. Topo-II works in a similar manner, with the difference that it cleaves both DNA strands, allowing the passage of an intact double helix through the break. The entire reaction takes place at the expense of ATP hydrolysis [6]. In contrast to topo-I, which is monomeric, two homologous but distinct isoforms of type II human topoisomerases have been identified, DNA topo-IIalpha and IIbeta [6, 7]. The alpha isoform is the type II topoisomerase that was originally described and characterized in mammalian species [6].
###end p 12
###begin p 13
###xml 97 98 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 100 101 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 210 212 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 485 486 473 474 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 596 597 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 599 600 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 602 604 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 749 750 733 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
Several studies have shown topo-IIalpha to be a reliable marker of cell proliferation in tumors [8, 9]. In contrast to topo-II, topo-I levels are not cycle-specific and remain stable throughout the cell cycle [10]. Topo-IIalpha plays important roles in DNA synthesis and transcription, as well as chromosomal segregation during mitosis. Beyond its physiological functions, topo-IIalpha is reported to be a sensitive and specific marker of actively proliferating cells (in the late S, G2 and M-phases of the cell cycle) and has been used as a proliferation marker in studies of colorectal cancer [7, 8, 10]. In addition to the well described role of the three MDR-related proteins, topo-IIalpha has been implicated in drug resistance of tumor cells [9].
###end p 13
###begin p 14
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
Topo-I catalytic activity has been evaluated in various studies and has been detected in all normal tissues at fairly constant levels [10]. Additional parameters were further investigated: topo-I immunoreactive protein levels were estimated by Western blot analysis, and topo-I gene expression (topo-I mRNA) was evaluated by Northern blot analysis. With regard to colorectal tumors, they were found to exhibit 5- to 35-fold increases in topo-I levels compared to the adjacent normal colonic mucosa [11].
###end p 14
###begin p 15
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 665 667 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 808 810 808 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 905 907 905 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 909 911 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR60">24</xref>
###xml 1140 1142 1140 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 87 92 <span type="species:ncbi:9606">human</span>
Topo-I expression has also been evaluated by immunohistochemistry in paraffin-embedded human tissues [12], and its expression has been demonstrated in numerous neoplastic tissues. Increased topo-I has been shown in ovarian carcinomas (elevated topo-I expression in 43% of tumors) [12]; colorectal carcinomas (ranging from 43-86% in various studies) [13-15]; testicular tumors (30-38% in seminomas, 30% in embryonal carcinomas, and 100% in teratomas and yolk sac tumors) [16]; transitional carcinoma of the bladder (overexpression in 77%) [17], and renal cell carcinomas (ranging from 36-100% according to grade) [18]; malignant melanomas (overexpression in 41.6%) [19]; gastric carcinomas (overexpression in 68%) [20]; sarcomas (high levels of topo-I in 13%) [21]; breast carcinomas (overexpression in 41%) [22], oral dysplasias, and squamous cell carcinomas (overexpression in 79 and 92%, respectively) [23, 24]. In normal tissues, topo-I expression appeared to be higher in the germinal centers of the tonsil and in the mucosal lymphocytes of the colon, while topo I positivity was also detected in the glandular epithelium of the colon [12].
###end p 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods
###end title 16
###begin title 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 17
###begin p 18
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">25</xref>
###xml 387 388 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 389 396 389 396 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 396 420 396 420 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="19">Patients characteristics</p>
###xml 396 420 396 420 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="19">Patients characteristics</p></caption>
###xml 430 431 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 420 432 420 432 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Patients (<italic>n</italic>)</td>
###xml 432 434 432 434 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">40</td>
###xml 420 434 420 434 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Patients (<italic>n</italic>)</td><td align="left">40</td></tr>
###xml 434 440 434 440 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Gender</td>
###xml 434 440 434 440 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="2">Gender</td></tr>
###xml 440 444 440 444 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Men</td>
###xml 444 446 444 446 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">25</td>
###xml 440 446 440 446 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Men</td><td align="left">25</td></tr>
###xml 446 452 446 452 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Women</td>
###xml 452 454 452 454 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">15</td>
###xml 446 454 446 454 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Women</td><td align="left">15</td></tr>
###xml 454 485 454 485 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Median age at diagnosis (years)</td>
###xml 485 495 485 495 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">58 (35&#8211;75)</td>
###xml 454 495 454 495 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Median age at diagnosis (years)</td><td align="left">58 (35&#8211;75)</td></tr>
###xml 495 524 495 524 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Performance status (WHO), 0&#8211;1</td>
###xml 524 526 524 526 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">40</td>
###xml 495 526 495 526 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Performance status (WHO), 0&#8211;1</td><td align="left">40</td></tr>
###xml 526 551 526 551 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Location of primary tumor</td>
###xml 526 551 526 551 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="2">Location of primary tumor</td></tr>
###xml 551 563 551 563 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Right colon</td>
###xml 563 564 563 564 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6</td>
###xml 551 564 551 564 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Right colon</td><td align="left">6</td></tr>
###xml 564 575 564 575 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Left colon</td>
###xml 575 577 575 577 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">28</td>
###xml 564 577 564 577 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Left colon</td><td align="left">28</td></tr>
###xml 577 584 577 584 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Rectum</td>
###xml 584 585 584 585 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6</td>
###xml 577 585 577 585 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Rectum</td><td align="left">6</td></tr>
###xml 585 599 585 599 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Stage (Dukes&#8217;)</td>
###xml 585 599 585 599 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="2">Stage (Dukes&#8217;)</td></tr>
###xml 599 602 599 602 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;B2</td>
###xml 602 604 602 604 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">13</td>
###xml 599 604 599 604 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;B2</td><td align="left">13</td></tr>
###xml 604 606 604 606 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;C</td>
###xml 606 608 606 608 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">27</td>
###xml 604 608 604 608 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;C</td><td align="left">27</td></tr>
###xml 608 615 608 615 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Relapse</td>
###xml 608 615 608 615 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="2">Relapse</td></tr>
###xml 615 621 615 621 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Local</td>
###xml 621 623 621 623 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">17</td>
###xml 615 623 615 623 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Local</td><td align="left">17</td></tr>
###xml 623 631 623 631 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Distant</td>
###xml 631 633 631 633 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">23</td>
###xml 623 633 623 633 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Distant</td><td align="left">23</td></tr>
###xml 633 648 633 648 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Differentiation</td>
###xml 633 648 633 648 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="2">Differentiation</td></tr>
###xml 648 653 648 653 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Well</td>
###xml 653 654 653 654 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2</td>
###xml 648 654 648 654 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Well</td><td align="left">2</td></tr>
###xml 654 663 654 663 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Moderate</td>
###xml 663 665 663 665 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">31</td>
###xml 654 665 654 665 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Moderate</td><td align="left">31</td></tr>
###xml 665 670 665 670 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;Poor</td>
###xml 670 671 670 671 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7</td>
###xml 665 671 665 671 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;Poor</td><td align="left">7</td></tr>
###xml 671 701 671 701 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Disease-free survival (months)</td>
###xml 701 717 701 717 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">18 (range, 6&#8211;79)</td>
###xml 671 717 671 717 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Disease-free survival (months)</td><td align="left">18 (range, 6&#8211;79)</td></tr>
###xml 420 717 420 717 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Patients (<italic>n</italic>)</td><td align="left">40</td></tr><tr><td align="left" colspan="2">Gender</td></tr><tr><td align="left">&#160;Men</td><td align="left">25</td></tr><tr><td align="left">&#160;Women</td><td align="left">15</td></tr><tr><td align="left">Median age at diagnosis (years)</td><td align="left">58 (35&#8211;75)</td></tr><tr><td align="left">Performance status (WHO), 0&#8211;1</td><td align="left">40</td></tr><tr><td align="left" colspan="2">Location of primary tumor</td></tr><tr><td align="left">&#160;Right colon</td><td align="left">6</td></tr><tr><td align="left">&#160;Left colon</td><td align="left">28</td></tr><tr><td align="left">&#160;Rectum</td><td align="left">6</td></tr><tr><td align="left" colspan="2">Stage (Dukes&#8217;)</td></tr><tr><td align="left">&#160;B2</td><td align="left">13</td></tr><tr><td align="left">&#160;C</td><td align="left">27</td></tr><tr><td align="left" colspan="2">Relapse</td></tr><tr><td align="left">&#160;Local</td><td align="left">17</td></tr><tr><td align="left">&#160;Distant</td><td align="left">23</td></tr><tr><td align="left" colspan="2">Differentiation</td></tr><tr><td align="left">&#160;Well</td><td align="left">2</td></tr><tr><td align="left">&#160;Moderate</td><td align="left">31</td></tr><tr><td align="left">&#160;Poor</td><td align="left">7</td></tr><tr><td align="left">Disease-free survival (months)</td><td align="left">18 (range, 6&#8211;79)</td></tr></tbody>
###xml 420 717 420 717 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><tbody><tr><td align="left">Patients (<italic>n</italic>)</td><td align="left">40</td></tr><tr><td align="left" colspan="2">Gender</td></tr><tr><td align="left">&#160;Men</td><td align="left">25</td></tr><tr><td align="left">&#160;Women</td><td align="left">15</td></tr><tr><td align="left">Median age at diagnosis (years)</td><td align="left">58 (35&#8211;75)</td></tr><tr><td align="left">Performance status (WHO), 0&#8211;1</td><td align="left">40</td></tr><tr><td align="left" colspan="2">Location of primary tumor</td></tr><tr><td align="left">&#160;Right colon</td><td align="left">6</td></tr><tr><td align="left">&#160;Left colon</td><td align="left">28</td></tr><tr><td align="left">&#160;Rectum</td><td align="left">6</td></tr><tr><td align="left" colspan="2">Stage (Dukes&#8217;)</td></tr><tr><td align="left">&#160;B2</td><td align="left">13</td></tr><tr><td align="left">&#160;C</td><td align="left">27</td></tr><tr><td align="left" colspan="2">Relapse</td></tr><tr><td align="left">&#160;Local</td><td align="left">17</td></tr><tr><td align="left">&#160;Distant</td><td align="left">23</td></tr><tr><td align="left" colspan="2">Differentiation</td></tr><tr><td align="left">&#160;Well</td><td align="left">2</td></tr><tr><td align="left">&#160;Moderate</td><td align="left">31</td></tr><tr><td align="left">&#160;Poor</td><td align="left">7</td></tr><tr><td align="left">Disease-free survival (months)</td><td align="left">18 (range, 6&#8211;79)</td></tr></tbody></table>
###xml 389 717 389 717 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="19">Patients characteristics</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">Patients (<italic>n</italic>)</td><td align="left">40</td></tr><tr><td align="left" colspan="2">Gender</td></tr><tr><td align="left">&#160;Men</td><td align="left">25</td></tr><tr><td align="left">&#160;Women</td><td align="left">15</td></tr><tr><td align="left">Median age at diagnosis (years)</td><td align="left">58 (35&#8211;75)</td></tr><tr><td align="left">Performance status (WHO), 0&#8211;1</td><td align="left">40</td></tr><tr><td align="left" colspan="2">Location of primary tumor</td></tr><tr><td align="left">&#160;Right colon</td><td align="left">6</td></tr><tr><td align="left">&#160;Left colon</td><td align="left">28</td></tr><tr><td align="left">&#160;Rectum</td><td align="left">6</td></tr><tr><td align="left" colspan="2">Stage (Dukes&#8217;)</td></tr><tr><td align="left">&#160;B2</td><td align="left">13</td></tr><tr><td align="left">&#160;C</td><td align="left">27</td></tr><tr><td align="left" colspan="2">Relapse</td></tr><tr><td align="left">&#160;Local</td><td align="left">17</td></tr><tr><td align="left">&#160;Distant</td><td align="left">23</td></tr><tr><td align="left" colspan="2">Differentiation</td></tr><tr><td align="left">&#160;Well</td><td align="left">2</td></tr><tr><td align="left">&#160;Moderate</td><td align="left">31</td></tr><tr><td align="left">&#160;Poor</td><td align="left">7</td></tr><tr><td align="left">Disease-free survival (months)</td><td align="left">18 (range, 6&#8211;79)</td></tr></tbody></table></table-wrap>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
###xml 290 294 <span type="species:ncbi:162683">Mayo</span>
###xml 339 347 <span type="species:ncbi:9606">Patients</span>
Forty patients with colorectal cancer that had recurred following surgery and adjuvant chemotherapy who underwent a second operation were included in this study. All had undergone surgical resection for their primary tumor and received post-operatively 5-FU-based [5FU and Leucovorin (LV), Mayo Clinic regimen] adjuvant chemotherapy [25]. Patients characteristics are described in Table 1.Table 1Patients characteristicsPatients (n)40Gender Men25 Women15Median age at diagnosis (years)58 (35-75)Performance status (WHO), 0-140Location of primary tumor Right colon6 Left colon28 Rectum6Stage (Dukes') B213 C27Relapse Local17 Distant23Differentiation Well2 Moderate31 Poor7Disease-free survival (months)18 (range, 6-79)
###end p 18
###begin p 19
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients characteristics
###end p 19
###begin title 20
Study plan
###end title 20
###begin p 21
Tumor tissue was collected during the initial operation from the primary tumor, before the administration of any adjuvant chemotherapy and also at the time of recurrence (during the second operation following chemotherapy). All these tissues were analyzed for expression of both topo-I and topo-IIalpha.
###end p 21
###begin title 22
Determination of topo-I and topo-IIalpha
###end title 22
###begin p 23
###xml 267 269 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">26</xref>
###xml 270 272 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">28</xref>
###xml 360 361 352 353 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 476 478 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">27</xref>
###xml 479 481 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">29</xref>
###xml 207 212 <span type="species:ncbi:10090">mouse</span>
###xml 346 351 <span type="species:ncbi:10090">mouse</span>
The expression of topo-I and topo-IIalpha was studied on paraffin sections by a standard three-step immunohistochemistry. Topogen, an anti-topo-I monoclonal antibody (mAb) (2012-3) was applied. Topogen is a mouse mAb (IgG2b isotype); its epitope has not been mapped [26-28]. The primary mAb JH2.7 for topo-IIalpha (Biocare Medical, CA, USA) is a mouse mAb (IgG1 isotype) that recognizes a 170-kDa protein, the epitope of which maps between aminoacid 854-1447 of topo-IIalpha [27-29]. Counterstaining with hematoxylin was applied in the end of the classical immunohistochemistry procedure.
###end p 23
###begin title 24
Positive and negative controls
###end title 24
###begin p 25
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">26</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">29</xref>
###xml 46 51 <span type="species:ncbi:9606">human</span>
For the expression of topo-I and -IIa, normal human tonsil tissues immunostaining served as positive controls. Non-specific, isotype-matched monoclonal Abs worked well as substitute negative controls [26-29].
###end p 25
###begin title 26
Determination of topo-I and topo-IIalpha expression
###end title 26
###begin p 27
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">First step</bold>
###xml 123 130 <span type="species:ncbi:9606">patient</span>
###xml 942 949 <span type="species:ncbi:9606">patient</span>
First step Sections were examined for quantified immunoreactivity by two independent investigators blinded to any relevant patient clinical data. They evaluated more than 1,000 neoplastic cells in consecutive areas of neoplastic tissue. The numbers of positive cells were then expressed as a percentage of labeled tumor cells with respect to the total number of tumor cells that were evaluated. Immunostaining for topo-I and -IIalpha was graded according to the percentage of tumor cells staining positive (and +/- for <5%, + for 5-50% and ++ for 50 to 75% of cells with positive staining) and intensity of staining (weakly positive, moderately positive, or strongly positive). To simplify the scoring, we graded them as 0 (negative cells), 1 (+/- and/or <5%), 2 (+ and/or 5-50%), 3 (++ and/or 50-75%). Then, the sections were evaluated classified in pairs (one section from the first surgery and one section from the second surgery for each patient).
###end p 27
###begin p 28
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Second step</bold>
Second step The percentages of immunoreactive malignant cells were calculated using an image analysis system with an appropriate software package [Sigma Scan Pro, Version 5.0 (SPSS Science, Erkrath, Germany)]. The ratio was calculated as a percentage of immunohistochemically positive neoplastic cells over the total number (stained and unstained) of neoplastic cells. The membrane, cytoplasmic or nuclear intensity of the specific immunohistochemical stain, was also assessed. All the positively stained cells were classified in two groups (weakly stained and strongly stained).
###end p 28
###begin p 29
DNA ploidy of neoplastic cells was evaluated by image DNA cytometry performed on Feulgen-stained sections. Images were acquired using a Zeiss Axiolab microscope (Carl Zeiss Jena GmbH, Jena, Germany) with a mechanical stage, fitted with a SONY-iris CCD video camera (SONY Corporation, Tokyo, Japan). The latter was connected to a Pentium II personal computer which included the relevant software. Slides were examined at low power magnification (40x) to identify the areas with the highest cellularity. In each case, a total number of >/=200 Feulgen-stained nuclei was selected at high power magnification (400x) and stored as JPEG file [1,550 x 1,070 pixels, 16.7 million colors (24-bit)]. Then the images were converted to gray scale and the staining intensity of the Feulgen-stained nuclei was measured semi-automatically. A classification of the nuclei in pairs according to their staining intensity followed. Finally, the graphic presentation of the nuclei demonstrating their distribution according to their DNA content was also performed.
###end p 29
###begin title 30
Statistical analysis
###end title 30
###begin p 31
###xml 437 438 437 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 500 507 <span type="species:ncbi:9606">patient</span>
All analyses were performed with SPSS version 10.1 (Statistical Product and Service Solutions; SPSS Inc., Chicago, IL, USA). We used McNemar's paired Chi-square test to assess the possible alteration of the levels of topoisomerases after chemotherapy with 5-FU. Fisher's exact test was performed in order to assess the possible relationship of topoisomerase increase with gender, Dukes' stage, tumor grade and localization. Mann-Whitney U Test was performed to assess a possible relationship between patient age and alteration in topoisomerases levels.
###end p 31
###begin title 32
Results
###end title 32
###begin title 33
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 33
###begin p 34
###xml 646 647 646 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
###xml 69 72 <span type="species:ncbi:9606">men</span>
###xml 85 90 <span type="species:ncbi:9606">women</span>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
###xml 514 522 <span type="species:ncbi:9606">patients</span>
###xml 654 662 <span type="species:ncbi:9606">patients</span>
Forty patients were included in the present study. Of these, 25 were men and 15 were women. The median age was 58 years (range, 35-75). All patients had a performance status (PS) of 0-1. Tumor localization at the time of diagnosis was: right colon 6, left colon 28, and rectum 6. According to pathological classification, 13 patients had Dukes B2 tumors, and the remaining 27 Dukes C. With regard to differentiation, 2 tumors were well differentiated, 31 moderately and, 7 were poorly differentiated. Of all these patients, 17 relapsed locally and 23 with distant metastases, with a median relapse-free interval of 18 (range, 6-79) months (Table 1). All patients who entered the trial were evaluable for analysis.
###end p 34
###begin title 35
Ploidy
###end title 35
###begin p 36
Out of 40 primary tumors, 12 were highly aneuploid and the remaining 28 were moderately aneuploid. There was no association between the degree of DNA aneuploidy and the expression of any of the analyzed markers.
###end p 36
###begin title 37
Topoisomerase I
###end title 37
###begin p 38
###xml 168 170 168 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 187 188 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 221 223 221 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 258 260 258 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 390 391 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 454 456 454 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 477 479 477 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 496 497 496 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 819 821 819 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 977 984 977 984 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 984 1011 984 1011 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39">Photomicroscopic evaluation</p>
###xml 984 1011 984 1011 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39">Photomicroscopic evaluation</p></caption>
###xml 1011 1030 1011 1030 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Examined parameters</th>
###xml 1030 1059 1030 1059 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Photo, microscopic evaluation</th>
###xml 1059 1060 1059 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1059 1060 1059 1060 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"><italic>P</italic></th>
###xml 1011 1060 1011 1060 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Examined parameters</th><th align="left" colspan="3">Photo, microscopic evaluation</th><th align="left" rowspan="2"><italic>P</italic></th></tr>
###xml 1060 1065 1060 1065 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Grade</th>
###xml 1065 1081 1065 1081 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">First evaluation</th>
###xml 1081 1098 1081 1098 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Second evaluation</th>
###xml 1060 1098 1060 1098 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Grade</th><th align="left">First evaluation</th><th align="left">Second evaluation</th></tr>
###xml 1011 1098 1011 1098 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2">Examined parameters</th><th align="left" colspan="3">Photo, microscopic evaluation</th><th align="left" rowspan="2"><italic>P</italic></th></tr><tr><th align="left">Grade</th><th align="left">First evaluation</th><th align="left">Second evaluation</th></tr></thead>
###xml 1098 1113 1098 1113 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="4">Topoisomerase I</td>
###xml 1113 1114 1113 1114 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1114 1115 1114 1115 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7</td>
###xml 1115 1116 1115 1116 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1116 1122 1116 1122 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0117</td>
###xml 1098 1122 1098 1122 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="4">Topoisomerase I</td><td char="." align="char">0</td><td char="." align="char">7</td><td char="." align="char">0</td><td char="." align="char">0.0117</td></tr>
###xml 1122 1123 1122 1123 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1123 1125 1123 1125 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13</td>
###xml 1125 1126 1125 1126 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1126 1132 1126 1132 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0007</td>
###xml 1122 1132 1122 1132 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">1</td><td char="." align="char">13</td><td char="." align="char">1</td><td char="." align="char">0.0007</td></tr>
###xml 1132 1133 1132 1133 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1133 1135 1133 1135 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">17</td>
###xml 1135 1137 1135 1137 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">26</td>
###xml 1137 1143 1137 1143 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0722</td>
###xml 1132 1143 1132 1143 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">2</td><td char="." align="char">17</td><td char="." align="char">26</td><td char="." align="char">0.0722</td></tr>
###xml 1143 1144 1143 1144 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 1144 1145 1144 1145 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 1145 1147 1145 1147 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13</td>
###xml 1147 1153 1147 1153 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0103</td>
###xml 1143 1153 1143 1153 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">3</td><td char="." align="char">3</td><td char="." align="char">13</td><td char="." align="char">0.0103</td></tr>
###xml 1197 1198 1197 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1153 1207 1153 1207 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" colspan="5">Increased: 25, decreased: 0, no change: 15, <italic>P</italic>&#160;=&#160;0.0001</td>
###xml 1153 1207 1153 1207 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char" colspan="5">Increased: 25, decreased: 0, no change: 15, <italic>P</italic>&#160;=&#160;0.0001</td></tr>
###xml 1207 1224 1207 1224 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="4">Topoisomerase IIa</td>
###xml 1224 1225 1224 1225 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1225 1226 1225 1226 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1226 1227 1226 1227 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1227 1228 1227 1228 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1207 1228 1207 1228 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" rowspan="4">Topoisomerase IIa</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td></tr>
###xml 1228 1229 1228 1229 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1229 1231 1229 1231 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 1231 1232 1231 1232 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1232 1238 1232 1238 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0252</td>
###xml 1228 1238 1228 1238 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">1</td><td char="." align="char">10</td><td char="." align="char">2</td><td char="." align="char">0.0252</td></tr>
###xml 1238 1239 1238 1239 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1239 1241 1239 1241 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">30</td>
###xml 1241 1243 1241 1243 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">28</td>
###xml 1243 1249 1243 1249 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.8027</td>
###xml 1238 1249 1238 1249 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">2</td><td char="." align="char">30</td><td char="." align="char">28</td><td char="." align="char">0.8027</td></tr>
###xml 1249 1250 1249 1250 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 1250 1251 1250 1251 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1251 1253 1251 1253 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 1253 1259 1253 1259 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0010</td>
###xml 1249 1259 1249 1259 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char">3</td><td char="." align="char">0</td><td char="." align="char">10</td><td char="." align="char">0.0010</td></tr>
###xml 1303 1304 1303 1304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1259 1313 1259 1313 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char" colspan="5">Increased: 18, decreased: 0, no change: 22, <italic>P</italic>&#160;=&#160;0.0001</td>
###xml 1259 1313 1259 1313 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td char="." align="char" colspan="5">Increased: 18, decreased: 0, no change: 22, <italic>P</italic>&#160;=&#160;0.0001</td></tr>
###xml 1098 1313 1098 1313 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left" rowspan="4">Topoisomerase I</td><td char="." align="char">0</td><td char="." align="char">7</td><td char="." align="char">0</td><td char="." align="char">0.0117</td></tr><tr><td char="." align="char">1</td><td char="." align="char">13</td><td char="." align="char">1</td><td char="." align="char">0.0007</td></tr><tr><td char="." align="char">2</td><td char="." align="char">17</td><td char="." align="char">26</td><td char="." align="char">0.0722</td></tr><tr><td char="." align="char">3</td><td char="." align="char">3</td><td char="." align="char">13</td><td char="." align="char">0.0103</td></tr><tr><td char="." align="char" colspan="5">Increased: 25, decreased: 0, no change: 15, <italic>P</italic>&#160;=&#160;0.0001</td></tr><tr><td align="left" rowspan="4">Topoisomerase IIa</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td></tr><tr><td char="." align="char">1</td><td char="." align="char">10</td><td char="." align="char">2</td><td char="." align="char">0.0252</td></tr><tr><td char="." align="char">2</td><td char="." align="char">30</td><td char="." align="char">28</td><td char="." align="char">0.8027</td></tr><tr><td char="." align="char">3</td><td char="." align="char">0</td><td char="." align="char">10</td><td char="." align="char">0.0010</td></tr><tr><td char="." align="char" colspan="5">Increased: 18, decreased: 0, no change: 22, <italic>P</italic>&#160;=&#160;0.0001</td></tr></tbody>
###xml 1011 1313 1011 1313 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Examined parameters</th><th align="left" colspan="3">Photo, microscopic evaluation</th><th align="left" rowspan="2"><italic>P</italic></th></tr><tr><th align="left">Grade</th><th align="left">First evaluation</th><th align="left">Second evaluation</th></tr></thead><tbody><tr><td align="left" rowspan="4">Topoisomerase I</td><td char="." align="char">0</td><td char="." align="char">7</td><td char="." align="char">0</td><td char="." align="char">0.0117</td></tr><tr><td char="." align="char">1</td><td char="." align="char">13</td><td char="." align="char">1</td><td char="." align="char">0.0007</td></tr><tr><td char="." align="char">2</td><td char="." align="char">17</td><td char="." align="char">26</td><td char="." align="char">0.0722</td></tr><tr><td char="." align="char">3</td><td char="." align="char">3</td><td char="." align="char">13</td><td char="." align="char">0.0103</td></tr><tr><td char="." align="char" colspan="5">Increased: 25, decreased: 0, no change: 15, <italic>P</italic>&#160;=&#160;0.0001</td></tr><tr><td align="left" rowspan="4">Topoisomerase IIa</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td></tr><tr><td char="." align="char">1</td><td char="." align="char">10</td><td char="." align="char">2</td><td char="." align="char">0.0252</td></tr><tr><td char="." align="char">2</td><td char="." align="char">30</td><td char="." align="char">28</td><td char="." align="char">0.8027</td></tr><tr><td char="." align="char">3</td><td char="." align="char">0</td><td char="." align="char">10</td><td char="." align="char">0.0010</td></tr><tr><td char="." align="char" colspan="5">Increased: 18, decreased: 0, no change: 22, <italic>P</italic>&#160;=&#160;0.0001</td></tr></tbody></table>
###xml 977 1313 977 1313 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="39">Photomicroscopic evaluation</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Examined parameters</th><th align="left" colspan="3">Photo, microscopic evaluation</th><th align="left" rowspan="2"><italic>P</italic></th></tr><tr><th align="left">Grade</th><th align="left">First evaluation</th><th align="left">Second evaluation</th></tr></thead><tbody><tr><td align="left" rowspan="4">Topoisomerase I</td><td char="." align="char">0</td><td char="." align="char">7</td><td char="." align="char">0</td><td char="." align="char">0.0117</td></tr><tr><td char="." align="char">1</td><td char="." align="char">13</td><td char="." align="char">1</td><td char="." align="char">0.0007</td></tr><tr><td char="." align="char">2</td><td char="." align="char">17</td><td char="." align="char">26</td><td char="." align="char">0.0722</td></tr><tr><td char="." align="char">3</td><td char="." align="char">3</td><td char="." align="char">13</td><td char="." align="char">0.0103</td></tr><tr><td char="." align="char" colspan="5">Increased: 25, decreased: 0, no change: 15, <italic>P</italic>&#160;=&#160;0.0001</td></tr><tr><td align="left" rowspan="4">Topoisomerase IIa</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td></tr><tr><td char="." align="char">1</td><td char="." align="char">10</td><td char="." align="char">2</td><td char="." align="char">0.0252</td></tr><tr><td char="." align="char">2</td><td char="." align="char">30</td><td char="." align="char">28</td><td char="." align="char">0.8027</td></tr><tr><td char="." align="char">3</td><td char="." align="char">0</td><td char="." align="char">10</td><td char="." align="char">0.0010</td></tr><tr><td char="." align="char" colspan="5">Increased: 18, decreased: 0, no change: 22, <italic>P</italic>&#160;=&#160;0.0001</td></tr></tbody></table></table-wrap>
###xml 1313 1319 1313 1319 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1319 1425 1319 1425 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40">Topoisomerase I (Topo-I) expression in relation to tumor grade according to immunohistochemical evaluation</p>
###xml 1319 1425 1319 1425 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40">Topoisomerase I (Topo-I) expression in relation to tumor grade according to immunohistochemical evaluation</p></caption>
###xml 1425 1425 1425 1425 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="280_2008_886_Fig1_HTML" id="MO1"/>
###xml 1313 1425 1313 1425 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="40">Topoisomerase I (Topo-I) expression in relation to tumor grade according to immunohistochemical evaluation</p></caption><graphic position="anchor" xlink:href="280_2008_886_Fig1_HTML" id="MO1"/></fig>
###xml 1425 1432 1425 1432 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 1432 1461 1432 1461 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41">Image analysis evaluation (%)</p>
###xml 1432 1461 1432 1461 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="41">Image analysis evaluation (%)</p></caption>
###xml 1461 1466 1461 1466 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Range</th>
###xml 1466 1484 1466 1484 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">First sample (no.)</th>
###xml 1484 1503 1484 1503 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Second sample (no.)</th>
###xml 1503 1504 1503 1504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1503 1504 1503 1504 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic></th>
###xml 1504 1509 1504 1509 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Range</th>
###xml 1509 1527 1509 1527 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">First sample (no.)</th>
###xml 1527 1546 1527 1546 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Second sample (no.)</th>
###xml 1546 1547 1546 1547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1546 1547 1546 1547 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic></th>
###xml 1461 1547 1461 1547 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Range</th><th align="left">First sample (no.)</th><th align="left">Second sample (no.)</th><th align="left"><italic>P</italic></th><th align="left">Range</th><th align="left">First sample (no.)</th><th align="left">Second sample (no.)</th><th align="left"><italic>P</italic></th></tr>
###xml 1461 1547 1461 1547 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Range</th><th align="left">First sample (no.)</th><th align="left">Second sample (no.)</th><th align="left"><italic>P</italic></th><th align="left">Range</th><th align="left">First sample (no.)</th><th align="left">Second sample (no.)</th><th align="left"><italic>P</italic></th></tr></thead>
###xml 1547 1562 1547 1562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Topoisomerase I</italic>
###xml 1547 1562 1547 1562 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Topoisomerase I</italic></td>
###xml 1562 1562 1562 1562 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1562 1562 1562 1562 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1562 1562 1562 1562 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1562 1562 1562 1562 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1562 1562 1562 1562 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1562 1562 1562 1562 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1562 1562 1562 1562 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1547 1562 1547 1562 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>Topoisomerase I</italic></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr>
###xml 1562 1563 1562 1563 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1563 1564 1563 1564 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1564 1565 1564 1565 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1565 1566 1565 1566 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1566 1571 1566 1571 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">36&#8211;40</td>
###xml 1571 1572 1571 1572 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 1572 1573 1572 1573 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1573 1579 1573 1579 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.2405</td>
###xml 1562 1579 1562 1579 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="&#8211;" align="char">36&#8211;40</td><td char="." align="char">3</td><td char="." align="char">0</td><td char="." align="char">0.2405</td></tr>
###xml 1579 1582 1579 1582 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1&#8211;5</td>
###xml 1582 1584 1582 1584 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21</td>
###xml 1584 1585 1584 1585 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1585 1591 1585 1591 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0001</td>
###xml 1591 1596 1591 1596 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">41&#8211;45</td>
###xml 1596 1597 1596 1597 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1597 1598 1597 1598 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1598 1603 1598 1603 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.000</td>
###xml 1579 1603 1579 1603 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">1&#8211;5</td><td char="." align="char">21</td><td char="." align="char">1</td><td char="." align="char">0.0001</td><td char="&#8211;" align="char">41&#8211;45</td><td char="." align="char">1</td><td char="." align="char">1</td><td char="." align="char">1.000</td></tr>
###xml 1603 1607 1603 1607 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6&#8211;10</td>
###xml 1607 1608 1607 1608 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 1608 1609 1608 1609 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1609 1615 1609 1615 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.1156</td>
###xml 1615 1620 1615 1620 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">46&#8211;50</td>
###xml 1620 1621 1620 1621 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1621 1622 1621 1622 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1622 1627 1622 1627 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.000</td>
###xml 1603 1627 1603 1627 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">6&#8211;10</td><td char="." align="char">4</td><td char="." align="char">0</td><td char="." align="char">0.1156</td><td char="&#8211;" align="char">46&#8211;50</td><td char="." align="char">1</td><td char="." align="char">1</td><td char="." align="char">1.000</td></tr>
###xml 1627 1632 1627 1632 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">11&#8211;15</td>
###xml 1632 1633 1632 1633 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1633 1634 1633 1634 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 1634 1640 1634 1640 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.6752</td>
###xml 1640 1645 1640 1645 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">51&#8211;55</td>
###xml 1645 1646 1645 1646 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1646 1647 1646 1647 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 1647 1653 1647 1653 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.6752</td>
###xml 1627 1653 1627 1653 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">11&#8211;15</td><td char="." align="char">2</td><td char="." align="char">4</td><td char="." align="char">0.6752</td><td char="&#8211;" align="char">51&#8211;55</td><td char="." align="char">2</td><td char="." align="char">4</td><td char="." align="char">0.6752</td></tr>
###xml 1653 1658 1653 1658 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">16&#8211;20</td>
###xml 1658 1659 1658 1659 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 1659 1660 1659 1660 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1660 1666 1660 1666 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.7119</td>
###xml 1666 1671 1666 1671 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">56&#8211;60</td>
###xml 1671 1672 1671 1672 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1672 1673 1672 1673 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 1673 1679 1673 1679 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.1156</td>
###xml 1653 1679 1653 1679 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">16&#8211;20</td><td char="." align="char">3</td><td char="." align="char">5</td><td char="." align="char">0.7119</td><td char="&#8211;" align="char">56&#8211;60</td><td char="." align="char">0</td><td char="." align="char">4</td><td char="." align="char">0.1156</td></tr>
###xml 1679 1684 1679 1684 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">21&#8211;25</td>
###xml 1684 1685 1684 1685 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1685 1686 1685 1686 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 1686 1687 1686 1687 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1687 1692 1687 1692 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">61&#8211;65</td>
###xml 1692 1693 1692 1693 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1693 1694 1693 1694 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1694 1700 1694 1700 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0547</td>
###xml 1679 1700 1679 1700 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">21&#8211;25</td><td char="." align="char">2</td><td char="." align="char">3</td><td char="." align="char">1</td><td char="&#8211;" align="char">61&#8211;65</td><td char="." align="char">0</td><td char="." align="char">5</td><td char="." align="char">0.0547</td></tr>
###xml 1700 1705 1700 1705 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">26&#8211;30</td>
###xml 1705 1706 1705 1706 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1706 1707 1706 1707 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9</td>
###xml 1707 1713 1707 1713 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0143</td>
###xml 1713 1718 1713 1718 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">66&#8211;70</td>
###xml 1718 1719 1718 1719 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1719 1720 1719 1720 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1720 1720 1720 1720 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1700 1720 1700 1720 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">26&#8211;30</td><td char="." align="char">1</td><td char="." align="char">9</td><td char="." align="char">0.0143</td><td char="&#8211;" align="char">66&#8211;70</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left"/></tr>
###xml 1720 1725 1720 1725 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">31&#8211;35</td>
###xml 1725 1726 1725 1726 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1726 1727 1726 1727 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 1727 1733 1727 1733 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.2405</td>
###xml 1733 1738 1733 1738 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">71&#8211;80</td>
###xml 1738 1739 1738 1739 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1739 1740 1739 1740 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1740 1740 1740 1740 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1720 1740 1720 1740 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">31&#8211;35</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">0.2405</td><td char="&#8211;" align="char">71&#8211;80</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left"/></tr>
###xml 1740 1757 1740 1757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Topoisomerase IIa</italic>
###xml 1740 1757 1740 1757 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Topoisomerase IIa</italic></td>
###xml 1757 1757 1757 1757 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1757 1757 1757 1757 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1757 1757 1757 1757 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1757 1757 1757 1757 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1757 1757 1757 1757 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1757 1757 1757 1757 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1757 1757 1757 1757 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1740 1757 1740 1757 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left"><italic>Topoisomerase IIa</italic></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr>
###xml 1757 1758 1757 1758 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0</td>
###xml 1758 1759 1758 1759 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1759 1760 1759 1760 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1760 1761 1760 1761 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1761 1766 1761 1766 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">36&#8211;40</td>
###xml 1766 1767 1766 1767 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1767 1768 1767 1768 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 1768 1769 1768 1769 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1757 1769 1757 1769 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="&#8211;" align="char">36&#8211;40</td><td char="." align="char">2</td><td char="." align="char">3</td><td char="." align="char">1</td></tr>
###xml 1769 1772 1769 1772 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1&#8211;5</td>
###xml 1772 1774 1772 1774 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 1774 1775 1774 1775 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 1775 1781 1775 1781 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.1395</td>
###xml 1781 1786 1781 1786 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">41&#8211;45</td>
###xml 1786 1787 1786 1787 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1787 1788 1787 1788 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1788 1794 1788 1794 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.2007</td>
###xml 1769 1794 1769 1794 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">1&#8211;5</td><td char="." align="char">10</td><td char="." align="char">4</td><td char="." align="char">0.1395</td><td char="&#8211;" align="char">41&#8211;45</td><td char="." align="char">5</td><td char="." align="char">1</td><td char="." align="char">0.2007</td></tr>
###xml 1794 1798 1794 1798 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6&#8211;10</td>
###xml 1798 1799 1798 1799 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1799 1800 1799 1800 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1800 1801 1800 1801 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1801 1806 1801 1806 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">46&#8211;50</td>
###xml 1806 1807 1806 1807 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1807 1808 1807 1808 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 1808 1814 1808 1814 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.2405</td>
###xml 1794 1814 1794 1814 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">6&#8211;10</td><td char="." align="char">6</td><td char="." align="char">5</td><td char="." align="char">1</td><td char="&#8211;" align="char">46&#8211;50</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">0.2405</td></tr>
###xml 1814 1819 1814 1819 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">11&#8211;15</td>
###xml 1819 1820 1819 1820 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1820 1821 1820 1821 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1821 1827 1821 1827 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.4315</td>
###xml 1827 1832 1827 1832 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">51&#8211;55</td>
###xml 1832 1833 1832 1833 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1833 1834 1833 1834 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1834 1840 1834 1840 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.4937</td>
###xml 1814 1840 1814 1840 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">11&#8211;15</td><td char="." align="char">5</td><td char="." align="char">2</td><td char="." align="char">0.4315</td><td char="&#8211;" align="char">51&#8211;55</td><td char="." align="char">0</td><td char="." align="char">2</td><td char="." align="char">0.4937</td></tr>
###xml 1840 1845 1840 1845 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">16&#8211;20</td>
###xml 1845 1846 1845 1846 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9</td>
###xml 1846 1847 1846 1847 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1847 1853 1847 1853 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0143</td>
###xml 1853 1858 1853 1858 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">56&#8211;60</td>
###xml 1858 1859 1858 1859 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1859 1860 1859 1860 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1860 1861 1860 1861 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1840 1861 1840 1861 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">16&#8211;20</td><td char="." align="char">9</td><td char="." align="char">1</td><td char="." align="char">0.0143</td><td char="&#8211;" align="char">56&#8211;60</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td></tr>
###xml 1861 1866 1861 1866 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">21&#8211;25</td>
###xml 1866 1867 1866 1867 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1867 1868 1867 1868 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1868 1874 1868 1874 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0547</td>
###xml 1874 1879 1874 1879 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">61&#8211;65</td>
###xml 1879 1880 1879 1880 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1880 1881 1880 1881 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1881 1882 1881 1882 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1861 1882 1861 1882 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">21&#8211;25</td><td char="." align="char">0</td><td char="." align="char">5</td><td char="." align="char">0.0547</td><td char="&#8211;" align="char">61&#8211;65</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="." align="char">1</td></tr>
###xml 1882 1887 1882 1887 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">26&#8211;30</td>
###xml 1887 1888 1887 1888 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 1888 1889 1888 1889 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 1889 1890 1889 1890 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1890 1895 1890 1895 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">66&#8211;70</td>
###xml 1895 1896 1895 1896 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1896 1897 1896 1897 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1897 1903 1897 1903 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.4937</td>
###xml 1882 1903 1882 1903 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">26&#8211;30</td><td char="." align="char">3</td><td char="." align="char">3</td><td char="." align="char">1</td><td char="&#8211;" align="char">66&#8211;70</td><td char="." align="char">0</td><td char="." align="char">2</td><td char="." align="char">0.4937</td></tr>
###xml 1903 1908 1903 1908 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">31&#8211;35</td>
###xml 1908 1909 1908 1909 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1909 1910 1909 1910 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 1910 1916 1910 1916 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.2405</td>
###xml 1916 1921 1916 1921 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#x2013;" align="char">71&#8211;80</td>
###xml 1921 1922 1921 1922 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1922 1923 1922 1923 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 1923 1929 1923 1929 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0547</td>
###xml 1903 1929 1903 1929 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">31&#8211;35</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">0.2405</td><td char="&#8211;" align="char">71&#8211;80</td><td char="." align="char">0</td><td char="." align="char">5</td><td char="." align="char">0.0547</td></tr>
###xml 1547 1929 1547 1929 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left"><italic>Topoisomerase I</italic></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="&#8211;" align="char">36&#8211;40</td><td char="." align="char">3</td><td char="." align="char">0</td><td char="." align="char">0.2405</td></tr><tr><td align="left">1&#8211;5</td><td char="." align="char">21</td><td char="." align="char">1</td><td char="." align="char">0.0001</td><td char="&#8211;" align="char">41&#8211;45</td><td char="." align="char">1</td><td char="." align="char">1</td><td char="." align="char">1.000</td></tr><tr><td align="left">6&#8211;10</td><td char="." align="char">4</td><td char="." align="char">0</td><td char="." align="char">0.1156</td><td char="&#8211;" align="char">46&#8211;50</td><td char="." align="char">1</td><td char="." align="char">1</td><td char="." align="char">1.000</td></tr><tr><td align="left">11&#8211;15</td><td char="." align="char">2</td><td char="." align="char">4</td><td char="." align="char">0.6752</td><td char="&#8211;" align="char">51&#8211;55</td><td char="." align="char">2</td><td char="." align="char">4</td><td char="." align="char">0.6752</td></tr><tr><td align="left">16&#8211;20</td><td char="." align="char">3</td><td char="." align="char">5</td><td char="." align="char">0.7119</td><td char="&#8211;" align="char">56&#8211;60</td><td char="." align="char">0</td><td char="." align="char">4</td><td char="." align="char">0.1156</td></tr><tr><td align="left">21&#8211;25</td><td char="." align="char">2</td><td char="." align="char">3</td><td char="." align="char">1</td><td char="&#8211;" align="char">61&#8211;65</td><td char="." align="char">0</td><td char="." align="char">5</td><td char="." align="char">0.0547</td></tr><tr><td align="left">26&#8211;30</td><td char="." align="char">1</td><td char="." align="char">9</td><td char="." align="char">0.0143</td><td char="&#8211;" align="char">66&#8211;70</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left"/></tr><tr><td align="left">31&#8211;35</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">0.2405</td><td char="&#8211;" align="char">71&#8211;80</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left"/></tr><tr><td align="left"><italic>Topoisomerase IIa</italic></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="&#8211;" align="char">36&#8211;40</td><td char="." align="char">2</td><td char="." align="char">3</td><td char="." align="char">1</td></tr><tr><td align="left">1&#8211;5</td><td char="." align="char">10</td><td char="." align="char">4</td><td char="." align="char">0.1395</td><td char="&#8211;" align="char">41&#8211;45</td><td char="." align="char">5</td><td char="." align="char">1</td><td char="." align="char">0.2007</td></tr><tr><td align="left">6&#8211;10</td><td char="." align="char">6</td><td char="." align="char">5</td><td char="." align="char">1</td><td char="&#8211;" align="char">46&#8211;50</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">0.2405</td></tr><tr><td align="left">11&#8211;15</td><td char="." align="char">5</td><td char="." align="char">2</td><td char="." align="char">0.4315</td><td char="&#8211;" align="char">51&#8211;55</td><td char="." align="char">0</td><td char="." align="char">2</td><td char="." align="char">0.4937</td></tr><tr><td align="left">16&#8211;20</td><td char="." align="char">9</td><td char="." align="char">1</td><td char="." align="char">0.0143</td><td char="&#8211;" align="char">56&#8211;60</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td></tr><tr><td align="left">21&#8211;25</td><td char="." align="char">0</td><td char="." align="char">5</td><td char="." align="char">0.0547</td><td char="&#8211;" align="char">61&#8211;65</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="." align="char">1</td></tr><tr><td align="left">26&#8211;30</td><td char="." align="char">3</td><td char="." align="char">3</td><td char="." align="char">1</td><td char="&#8211;" align="char">66&#8211;70</td><td char="." align="char">0</td><td char="." align="char">2</td><td char="." align="char">0.4937</td></tr><tr><td align="left">31&#8211;35</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">0.2405</td><td char="&#8211;" align="char">71&#8211;80</td><td char="." align="char">0</td><td char="." align="char">5</td><td char="." align="char">0.0547</td></tr></tbody>
###xml 1461 1929 1461 1929 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Range</th><th align="left">First sample (no.)</th><th align="left">Second sample (no.)</th><th align="left"><italic>P</italic></th><th align="left">Range</th><th align="left">First sample (no.)</th><th align="left">Second sample (no.)</th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left"><italic>Topoisomerase I</italic></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="&#8211;" align="char">36&#8211;40</td><td char="." align="char">3</td><td char="." align="char">0</td><td char="." align="char">0.2405</td></tr><tr><td align="left">1&#8211;5</td><td char="." align="char">21</td><td char="." align="char">1</td><td char="." align="char">0.0001</td><td char="&#8211;" align="char">41&#8211;45</td><td char="." align="char">1</td><td char="." align="char">1</td><td char="." align="char">1.000</td></tr><tr><td align="left">6&#8211;10</td><td char="." align="char">4</td><td char="." align="char">0</td><td char="." align="char">0.1156</td><td char="&#8211;" align="char">46&#8211;50</td><td char="." align="char">1</td><td char="." align="char">1</td><td char="." align="char">1.000</td></tr><tr><td align="left">11&#8211;15</td><td char="." align="char">2</td><td char="." align="char">4</td><td char="." align="char">0.6752</td><td char="&#8211;" align="char">51&#8211;55</td><td char="." align="char">2</td><td char="." align="char">4</td><td char="." align="char">0.6752</td></tr><tr><td align="left">16&#8211;20</td><td char="." align="char">3</td><td char="." align="char">5</td><td char="." align="char">0.7119</td><td char="&#8211;" align="char">56&#8211;60</td><td char="." align="char">0</td><td char="." align="char">4</td><td char="." align="char">0.1156</td></tr><tr><td align="left">21&#8211;25</td><td char="." align="char">2</td><td char="." align="char">3</td><td char="." align="char">1</td><td char="&#8211;" align="char">61&#8211;65</td><td char="." align="char">0</td><td char="." align="char">5</td><td char="." align="char">0.0547</td></tr><tr><td align="left">26&#8211;30</td><td char="." align="char">1</td><td char="." align="char">9</td><td char="." align="char">0.0143</td><td char="&#8211;" align="char">66&#8211;70</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left"/></tr><tr><td align="left">31&#8211;35</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">0.2405</td><td char="&#8211;" align="char">71&#8211;80</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left"/></tr><tr><td align="left"><italic>Topoisomerase IIa</italic></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="&#8211;" align="char">36&#8211;40</td><td char="." align="char">2</td><td char="." align="char">3</td><td char="." align="char">1</td></tr><tr><td align="left">1&#8211;5</td><td char="." align="char">10</td><td char="." align="char">4</td><td char="." align="char">0.1395</td><td char="&#8211;" align="char">41&#8211;45</td><td char="." align="char">5</td><td char="." align="char">1</td><td char="." align="char">0.2007</td></tr><tr><td align="left">6&#8211;10</td><td char="." align="char">6</td><td char="." align="char">5</td><td char="." align="char">1</td><td char="&#8211;" align="char">46&#8211;50</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">0.2405</td></tr><tr><td align="left">11&#8211;15</td><td char="." align="char">5</td><td char="." align="char">2</td><td char="." align="char">0.4315</td><td char="&#8211;" align="char">51&#8211;55</td><td char="." align="char">0</td><td char="." align="char">2</td><td char="." align="char">0.4937</td></tr><tr><td align="left">16&#8211;20</td><td char="." align="char">9</td><td char="." align="char">1</td><td char="." align="char">0.0143</td><td char="&#8211;" align="char">56&#8211;60</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td></tr><tr><td align="left">21&#8211;25</td><td char="." align="char">0</td><td char="." align="char">5</td><td char="." align="char">0.0547</td><td char="&#8211;" align="char">61&#8211;65</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="." align="char">1</td></tr><tr><td align="left">26&#8211;30</td><td char="." align="char">3</td><td char="." align="char">3</td><td char="." align="char">1</td><td char="&#8211;" align="char">66&#8211;70</td><td char="." align="char">0</td><td char="." align="char">2</td><td char="." align="char">0.4937</td></tr><tr><td align="left">31&#8211;35</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">0.2405</td><td char="&#8211;" align="char">71&#8211;80</td><td char="." align="char">0</td><td char="." align="char">5</td><td char="." align="char">0.0547</td></tr></tbody></table>
###xml 1929 1934 1929 1934 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Total</th>
###xml 1934 1953 1934 1953 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">First determination</th>
###xml 1953 1973 1953 1973 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Second determination</th>
###xml 1973 1974 1973 1974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1973 1974 1973 1974 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2"><italic>P</italic></th>
###xml 1929 1974 1929 1974 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Total</th><th align="left" colspan="3">First determination</th><th align="left" colspan="3">Second determination</th><th align="left" rowspan="2"><italic>P</italic></th></tr>
###xml 1974 1978 1974 1978 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean</th>
###xml 1978 1984 1978 1984 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Median</th>
###xml 1984 1989 1984 1989 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Range</th>
###xml 1989 1993 1989 1993 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Mean</th>
###xml 1993 1999 1993 1999 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Median</th>
###xml 1999 2004 1999 2004 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Range</th>
###xml 1974 2004 1974 2004 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Mean</th><th align="left">Median</th><th align="left">Range</th><th align="left">Mean</th><th align="left">Median</th><th align="left">Range</th></tr>
###xml 1929 2004 1929 2004 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2">Total</th><th align="left" colspan="3">First determination</th><th align="left" colspan="3">Second determination</th><th align="left" rowspan="2"><italic>P</italic></th></tr><tr><th align="left">Mean</th><th align="left">Median</th><th align="left">Range</th><th align="left">Mean</th><th align="left">Median</th><th align="left">Range</th></tr></thead>
###xml 2004 2019 2004 2019 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Topoisomerase I</td>
###xml 2019 2025 2019 2025 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">13.875</td>
###xml 2025 2028 2025 2028 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.5</td>
###xml 2028 2032 2028 2032 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1&#8211;54</td>
###xml 2032 2038 2032 2038 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">35.375</td>
###xml 2038 2042 2038 2042 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">29.5</td>
###xml 2042 2046 2042 2046 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4&#8211;65</td>
###xml 2046 2052 2046 2052 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.0001</td>
###xml 2004 2052 2004 2052 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Topoisomerase I</td><td align="left">13.875</td><td char="." align="char">4.5</td><td align="left">1&#8211;54</td><td align="left">35.375</td><td char="." align="char">29.5</td><td align="left">4&#8211;65</td><td align="left">0.0001</td></tr>
###xml 2052 2069 2052 2069 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Topoisomerase IIa</td>
###xml 2069 2075 2069 2075 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">16.775</td>
###xml 2075 2077 2075 2077 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">15</td>
###xml 2077 2081 2077 2081 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1&#8211;45</td>
###xml 2081 2087 2081 2087 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">34.575</td>
###xml 2087 2089 2087 2089 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">31</td>
###xml 2089 2093 2089 2093 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2&#8211;79</td>
###xml 2093 2099 2093 2099 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.0001</td>
###xml 2052 2099 2052 2099 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Topoisomerase IIa</td><td align="left">16.775</td><td char="." align="char">15</td><td align="left">1&#8211;45</td><td align="left">34.575</td><td char="." align="char">31</td><td align="left">2&#8211;79</td><td align="left">0.0001</td></tr>
###xml 2004 2099 2004 2099 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Topoisomerase I</td><td align="left">13.875</td><td char="." align="char">4.5</td><td align="left">1&#8211;54</td><td align="left">35.375</td><td char="." align="char">29.5</td><td align="left">4&#8211;65</td><td align="left">0.0001</td></tr><tr><td align="left">Topoisomerase IIa</td><td align="left">16.775</td><td char="." align="char">15</td><td align="left">1&#8211;45</td><td align="left">34.575</td><td char="." align="char">31</td><td align="left">2&#8211;79</td><td align="left">0.0001</td></tr></tbody>
###xml 1929 2099 1929 2099 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Total</th><th align="left" colspan="3">First determination</th><th align="left" colspan="3">Second determination</th><th align="left" rowspan="2"><italic>P</italic></th></tr><tr><th align="left">Mean</th><th align="left">Median</th><th align="left">Range</th><th align="left">Mean</th><th align="left">Median</th><th align="left">Range</th></tr></thead><tbody><tr><td align="left">Topoisomerase I</td><td align="left">13.875</td><td char="." align="char">4.5</td><td align="left">1&#8211;54</td><td align="left">35.375</td><td char="." align="char">29.5</td><td align="left">4&#8211;65</td><td align="left">0.0001</td></tr><tr><td align="left">Topoisomerase IIa</td><td align="left">16.775</td><td char="." align="char">15</td><td align="left">1&#8211;45</td><td align="left">34.575</td><td char="." align="char">31</td><td align="left">2&#8211;79</td><td align="left">0.0001</td></tr></tbody></table>
###xml 1425 2099 1425 2099 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="41">Image analysis evaluation (%)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Range</th><th align="left">First sample (no.)</th><th align="left">Second sample (no.)</th><th align="left"><italic>P</italic></th><th align="left">Range</th><th align="left">First sample (no.)</th><th align="left">Second sample (no.)</th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left"><italic>Topoisomerase I</italic></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="&#8211;" align="char">36&#8211;40</td><td char="." align="char">3</td><td char="." align="char">0</td><td char="." align="char">0.2405</td></tr><tr><td align="left">1&#8211;5</td><td char="." align="char">21</td><td char="." align="char">1</td><td char="." align="char">0.0001</td><td char="&#8211;" align="char">41&#8211;45</td><td char="." align="char">1</td><td char="." align="char">1</td><td char="." align="char">1.000</td></tr><tr><td align="left">6&#8211;10</td><td char="." align="char">4</td><td char="." align="char">0</td><td char="." align="char">0.1156</td><td char="&#8211;" align="char">46&#8211;50</td><td char="." align="char">1</td><td char="." align="char">1</td><td char="." align="char">1.000</td></tr><tr><td align="left">11&#8211;15</td><td char="." align="char">2</td><td char="." align="char">4</td><td char="." align="char">0.6752</td><td char="&#8211;" align="char">51&#8211;55</td><td char="." align="char">2</td><td char="." align="char">4</td><td char="." align="char">0.6752</td></tr><tr><td align="left">16&#8211;20</td><td char="." align="char">3</td><td char="." align="char">5</td><td char="." align="char">0.7119</td><td char="&#8211;" align="char">56&#8211;60</td><td char="." align="char">0</td><td char="." align="char">4</td><td char="." align="char">0.1156</td></tr><tr><td align="left">21&#8211;25</td><td char="." align="char">2</td><td char="." align="char">3</td><td char="." align="char">1</td><td char="&#8211;" align="char">61&#8211;65</td><td char="." align="char">0</td><td char="." align="char">5</td><td char="." align="char">0.0547</td></tr><tr><td align="left">26&#8211;30</td><td char="." align="char">1</td><td char="." align="char">9</td><td char="." align="char">0.0143</td><td char="&#8211;" align="char">66&#8211;70</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left"/></tr><tr><td align="left">31&#8211;35</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">0.2405</td><td char="&#8211;" align="char">71&#8211;80</td><td char="." align="char">0</td><td char="." align="char">0</td><td align="left"/></tr><tr><td align="left"><italic>Topoisomerase IIa</italic></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="&#8211;" align="char">36&#8211;40</td><td char="." align="char">2</td><td char="." align="char">3</td><td char="." align="char">1</td></tr><tr><td align="left">1&#8211;5</td><td char="." align="char">10</td><td char="." align="char">4</td><td char="." align="char">0.1395</td><td char="&#8211;" align="char">41&#8211;45</td><td char="." align="char">5</td><td char="." align="char">1</td><td char="." align="char">0.2007</td></tr><tr><td align="left">6&#8211;10</td><td char="." align="char">6</td><td char="." align="char">5</td><td char="." align="char">1</td><td char="&#8211;" align="char">46&#8211;50</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">0.2405</td></tr><tr><td align="left">11&#8211;15</td><td char="." align="char">5</td><td char="." align="char">2</td><td char="." align="char">0.4315</td><td char="&#8211;" align="char">51&#8211;55</td><td char="." align="char">0</td><td char="." align="char">2</td><td char="." align="char">0.4937</td></tr><tr><td align="left">16&#8211;20</td><td char="." align="char">9</td><td char="." align="char">1</td><td char="." align="char">0.0143</td><td char="&#8211;" align="char">56&#8211;60</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">1</td></tr><tr><td align="left">21&#8211;25</td><td char="." align="char">0</td><td char="." align="char">5</td><td char="." align="char">0.0547</td><td char="&#8211;" align="char">61&#8211;65</td><td char="." align="char">0</td><td char="." align="char">1</td><td char="." align="char">1</td></tr><tr><td align="left">26&#8211;30</td><td char="." align="char">3</td><td char="." align="char">3</td><td char="." align="char">1</td><td char="&#8211;" align="char">66&#8211;70</td><td char="." align="char">0</td><td char="." align="char">2</td><td char="." align="char">0.4937</td></tr><tr><td align="left">31&#8211;35</td><td char="." align="char">0</td><td char="." align="char">3</td><td char="." align="char">0.2405</td><td char="&#8211;" align="char">71&#8211;80</td><td char="." align="char">0</td><td char="." align="char">5</td><td char="." align="char">0.0547</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Total</th><th align="left" colspan="3">First determination</th><th align="left" colspan="3">Second determination</th><th align="left" rowspan="2"><italic>P</italic></th></tr><tr><th align="left">Mean</th><th align="left">Median</th><th align="left">Range</th><th align="left">Mean</th><th align="left">Median</th><th align="left">Range</th></tr></thead><tbody><tr><td align="left">Topoisomerase I</td><td align="left">13.875</td><td char="." align="char">4.5</td><td align="left">1&#8211;54</td><td align="left">35.375</td><td char="." align="char">29.5</td><td align="left">4&#8211;65</td><td align="left">0.0001</td></tr><tr><td align="left">Topoisomerase IIa</td><td align="left">16.775</td><td char="." align="char">15</td><td align="left">1&#8211;45</td><td align="left">34.575</td><td char="." align="char">31</td><td align="left">2&#8211;79</td><td align="left">0.0001</td></tr></tbody></table></table-wrap>
###xml 780 788 <span type="species:ncbi:9606">patients</span>
###xml 831 839 <span type="species:ncbi:9606">Patients</span>
###xml 925 933 <span type="species:ncbi:9606">patients</span>
Immunohistochemical analysis revealed that levels of topo-I expression were higher in malignant cells from tumor recurrences compared to cells from the primary tumors (P = 0.0001) (Table 2; Fig. 1); decreased in grade 1 (P = 0.007) and increased in grade 3 (P = 0.003) (Table 2). In image analysis evaluation, there was a significant increase in malignant cells from the tumor recurrences (P = 0.0001) (Table 3); low expression was noticed in range 1-5 (P = 0.0001) and 26-30 (P = 0.0143) (Table 3; Fig. 3). The increase in topo-I levels was not significantly correlated with gender, performance status (WHO), location of the primary tumor, Dukes' stage, grade of differentiation, and localization of relapse. There was a statistically significant relationship between the age of patients and the expression of topo-I (P = 0.011). Patients with an increased expression of topo-I levels were older in age (median = 62.5) than patients without increased expression (median = 50).Table 2Photomicroscopic evaluationExamined parametersPhoto, microscopic evaluationPGradeFirst evaluationSecond evaluationTopoisomerase I0700.011711310.0007217260.072233130.0103Increased: 25, decreased: 0, no change: 15, P = 0.0001Topoisomerase IIa000111020.0252230280.802730100.0010Increased: 18, decreased: 0, no change: 22, P = 0.0001Fig. 1Topoisomerase I (Topo-I) expression in relation to tumor grade according to immunohistochemical evaluationTable 3Image analysis evaluation (%)RangeFirst sample (no.)Second sample (no.)PRangeFirst sample (no.)Second sample (no.)PTopoisomerase I000136-40300.24051-52110.000141-45111.0006-10400.115646-50111.00011-15240.675251-55240.675216-20350.711956-60040.115621-2523161-65050.054726-30190.014366-700031-35030.240571-8000Topoisomerase IIa000136-402311-51040.139541-45510.20076-1065146-50030.240511-15520.431551-55020.493716-20910.014356-6000121-25050.054761-6501126-3033166-70020.493731-35030.240571-80050.0547TotalFirst determinationSecond determinationPMeanMedianRangeMeanMedianRangeTopoisomerase I13.8754.51-5435.37529.54-650.0001Topoisomerase IIa16.775151-4534.575312-790.0001
###end p 38
###begin p 39
Photomicroscopic evaluation
###end p 39
###begin p 40
Topoisomerase I (Topo-I) expression in relation to tumor grade according to immunohistochemical evaluation
###end p 40
###begin p 41
Image analysis evaluation (%)
###end p 41
###begin title 42
Topoisomerase IIalpha
###end title 42
###begin p 43
###xml 144 146 144 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 163 164 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 171 172 171 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 231 233 231 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 250 251 250 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 357 359 357 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 430 432 430 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 449 450 449 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 584 586 580 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 723 725 715 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 872 874 860 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 1139 1141 1119 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P&#160;</italic>
###xml 1151 1157 1131 1137 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1157 1275 1137 1247 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="44">Topoisomerase II&#945; (Topo-II&#945;) expression in relation to tumor grade according to immunohistochemical evaluation</p>
###xml 1157 1275 1137 1247 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="44">Topoisomerase II&#945; (Topo-II&#945;) expression in relation to tumor grade according to immunohistochemical evaluation</p></caption>
###xml 1275 1275 1247 1247 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="280_2008_886_Fig2_HTML" id="MO2"/>
###xml 1151 1275 1131 1247 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="44">Topoisomerase II&#945; (Topo-II&#945;) expression in relation to tumor grade according to immunohistochemical evaluation</p></caption><graphic position="anchor" xlink:href="280_2008_886_Fig2_HTML" id="MO2"/></fig>
###xml 523 531 <span type="species:ncbi:9606">patients</span>
###xml 814 822 <span type="species:ncbi:9606">patients</span>
Malignant cells from tumor recurrences showed statistically significantly increased levels of topo-II, compared to those of the primary tumors (P = 0.0001) (Table 2; Fig. 2); while topo-II levels were decreased in grade 3 lesions (P = 0.0001) (Table 2; Fig. 4). In image analysis, there was a significant increase in malignant cells from tumor recurrences (P = 0.0001) (Table 3); low expression was noticed in the range of 16-20 (P = 0.0143) (Table 3). There was a statistically significant relationship between the age of patients and increased levels of expression of topo-IIalpha (P = 0.011). Levels of topo-IIalpha expression were higher in malignant cells from tumor recurrences compared to cells from primary tumors (P = 0.0001). There was a statistically significant positive correlation between the age of patients and increased levels of expression topo-IIalpha (P = 0.011). The increase in topo-IIalpha levels did not demonstrate any significant correlations with gender, age, PS (WHO), localization of primary tumor, Dukes' stage, tumor grade, and location of relapse when compared to topo-IIalpha levels in the primary tumors (P = 0.0001).Fig. 2Topoisomerase IIalpha (Topo-IIalpha) expression in relation to tumor grade according to immunohistochemical evaluation
###end p 43
###begin p 44
Topoisomerase IIalpha (Topo-IIalpha) expression in relation to tumor grade according to immunohistochemical evaluation
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 112 113 112 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 662 663 658 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 670 671 666 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 787 788 783 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 861 862 857 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 864 870 860 866 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 870 966 866 959 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47">Dispersion diagram of topoisomerase I (Topo-&#921;) expression as assessed by immunohistochemistry</p>
###xml 870 966 866 959 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="47">Dispersion diagram of topoisomerase I (Topo-&#921;) expression as assessed by immunohistochemistry</p></caption>
###xml 966 966 959 959 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="280_2008_886_Fig3_HTML" id="MO3"/>
###xml 864 966 860 959 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="47">Dispersion diagram of topoisomerase I (Topo-&#921;) expression as assessed by immunohistochemistry</p></caption><graphic position="anchor" xlink:href="280_2008_886_Fig3_HTML" id="MO3"/></fig>
###xml 966 972 959 965 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 972 1078 965 1060 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="48">Dispersion diagram of topoisomerase I&#921;&#945; Topo-II&#913; expression as assessed by immunohistochemistry</p>
###xml 972 1078 965 1060 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="48">Dispersion diagram of topoisomerase I&#921;&#945; Topo-II&#913; expression as assessed by immunohistochemistry</p></caption>
###xml 1078 1078 1060 1060 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="280_2008_886_Fig4_HTML" id="MO4"/>
###xml 966 1078 959 1060 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="48">Dispersion diagram of topoisomerase I&#921;&#945; Topo-II&#913; expression as assessed by immunohistochemistry</p></caption><graphic position="anchor" xlink:href="280_2008_886_Fig4_HTML" id="MO4"/></fig>
In our study, 33 out of 40 (83%) samples of colorectal cancer stained positive for topoisomerase (Table 2; Fig. 3). This finding is in close agreement with the results of Staley et al. [14], who reported 86% of positive staining in 29 samples, but in contrast with the results from Boonsong et al. [13], who demonstrated a lower percentage of cells expressing topo-I; 51% of the samples, including 24.4% with >50% positive tumor cells [13]. Topo-I immunoreactivity was confined to the nucleus in all samples, being consistent with the role of topo-I as a nuclear protein. For topo-IIalpha, 21 out of 40 (52%) samples of colorectal cancer stained positive (Table 2; Fig. 4), including 10/40 (25%) with weak positive staining (grade 1). This finding was confirmed by Image Analysis (Table 3). These data are consistent with those reported by Burden and Osheroff [6].Fig. 3Dispersion diagram of topoisomerase I (Topo-Iota) expression as assessed by immunohistochemistryFig. 4Dispersion diagram of topoisomerase IIotaalpha Topo-IIAlpha expression as assessed by immunohistochemistry
###end p 46
###begin p 47
Dispersion diagram of topoisomerase I (Topo-Iota) expression as assessed by immunohistochemistry
###end p 47
###begin p 48
Dispersion diagram of topoisomerase IIotaalpha Topo-IIAlpha expression as assessed by immunohistochemistry
###end p 48
###begin p 49
###xml 303 305 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 307 309 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">30</xref>
###xml 447 449 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 620 621 609 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 687 689 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
In this study, we present significantly increased topo-I and topo-IIotaalpha expression in recurrent colorectal tumors, reinforcing the view that their expression is likely part of the malignant cells phenotype in recurrent colorectal carcinomas. This observation is in agreement with previous studies [15, 30], which demonstrated a direct correlation between thymidylate synthase (TS) and topo-I tumor expression and hypothesized, similar to TS [31], that high topo-I expression is related to a more aggressive biological phenotype. Of note, increased topo-IIalpha expression characterizes rapidly proliferating cells [6] and represents an accepted marker of aggressive tumor behavior [32].
###end p 49
###begin p 50
###xml 245 247 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 365 367 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
Since the increase of topo-I and -IIalpha expression was demonstrated following 5-FU-based treatment, it is tempting to attribute this change to 5-FU. High levels of topo-I correlate with sensitivity to camptothecins (irinotecan and topotecan) [17], whereas high levels of topo-IIalpha correlate with sensitivity to etoposide, a known topo-IIalpha-targeting agent [32]. Thus, it is reasonable to consider applying these agents sequentially for the treatment of colorectal cancer; i.e. 5-FU --> irinotecan and 5-FU --> etoposide.
###end p 50
###begin p 51
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 203 211 <span type="species:ncbi:9606">patients</span>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
Irinotecan (CPT-11), a water soluble camptothecin derivative, is a specific potent inhibitor of topo-I [33]. In a European phase II study, irinotecan achieved response rates of 19% in chemotherapy-naive patients and 18% in pretreated patients with advanced disease [34].
###end p 51
###begin p 52
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
Drugs that target topo-II, such as etoposide (VP-16), doxorubicin, and mitoxantrone, are among the most effective anticancer drugs in clinical use. Etoposide destroys cells by inhibiting the ability of topo-II to ligate nucleic acids cleaved during the double-stranded DNA passage reaction [35].
###end p 52
###begin p 53
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">36</xref>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">44</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">45</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">47</xref>
###xml 633 635 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 303 311 <span type="species:ncbi:9606">patients</span>
Irinotecan yielded response rates of 15-25% in 5-FU-refractory patients [36-44], not dissimilar to those observed in first-line treatment of colorectal cancer (18-32%) [45-47] and in contrast to the expected decreasing response rate from the application of irinotecan in second-line treatment. Treating patients with irinotecan upon progression to 5-FU/LV seems to be yielding more significant results compared to the opposite sequence, based in our previous experience, where the best results with sequential monotherapies were obtained when 5-FU/LV was followed by irinotecan (5-FU/LV --> CPT11) at disease progression or relapse [41].
###end p 53
###begin p 54
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
With regard to irinotecan efficacy, in vitro data suggest that topo-I expression could be regarded as an important cellular sensitivity determinant [16]. In particular, decreased DNA topo-I expression was correlated with camptothecin-resistant cell lines [27], while Jansen et al. [36] reported a positive correlation between irinotecan sensitivity and topo-I activity.
###end p 54
###begin p 55
###xml 173 175 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 380 382 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">48</xref>
###xml 383 385 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">51</xref>
###xml 494 496 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">52</xref>
###xml 498 500 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR52">53</xref>
###xml 615 617 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">54</xref>
###xml 828 830 824 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">55</xref>
###xml 832 834 828 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR55">56</xref>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 784 792 <span type="species:ncbi:9606">patients</span>
Topo-IIalpha is the primary cytotoxic target of some of the most effective chemotherapeutic drugs, such as the epipodophylotoxins, etoposide (VP-16) and teniposide (VM-26) [32]. Studies in previously untreated patients with advanced colorectal carcinoma evaluating the combination of etoposide with cisplatin or 5-FU demonstrated minimal activity in metastatic colorectal cancer [48-51]; there have been no clinical data supporting the in vitro synergy observed between these cytotoxic agents [52, 53]. Other studies failed to prove any benefit with the combination of etoposide with 5-FU or cisplatin/carboplatin [54]. However, the combination of etoposide with 5-FU + LV had demonstrated some activity when administered as second-line treatment after failure of weekly 5-FU + LV in patients with metastatic colorectal cancer [55, 56].
###end p 55
###begin p 56
The results reported herein underscore the role of topoisomerase (topo-I and topo-IIalpha) expression in colorectal cancer. It is believed that translational studies of molecular targets for currently applied cytotoxic and biological agents (like bevacizumab and cetuximab) might form the basis of current and future drug combinations, in rationalizing the optimal chemotherapeutic drug schedule and sequence that, will eventually translate in improved tumor eradication and survival prolongation.
###end p 56
###begin p 57
We thank Dimitris Boulamatsis for the statistical analysis of the manuscript and Madalena Zlovotska for collection of the data. This trial was supported by a grant from ELKE 80546 of the University of Athens School of Medicine.
###end p 57
###begin p 58
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 58
###begin title 59
References
###end title 59
###begin article-title 60
Eukaryotic DNA topoisomerases I
###end article-title 60
###begin article-title 61
Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
###end article-title 61
###begin article-title 62
###xml 29 34 <span type="species:ncbi:9606">human</span>
A model for the mechanism of human topoisomerase I
###end article-title 62
###begin article-title 63
DNA topoisomerase I is involved in both repression and activation of transcription
###end article-title 63
###begin article-title 64
###xml 57 64 <span type="species:ncbi:9606">patient</span>
Purification of DNA topoisomerase I from the spleen of a patient with non-Hodgkin's lymphoma
###end article-title 64
###begin article-title 65
Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme
###end article-title 65
###begin article-title 66
Comparative genomic hybridization. Synchronous occurrence of focal nodular hyperplasia and hepatocellular carcinoma in the same liver is not based on common chromosomal aberrations
###end article-title 66
###begin article-title 67
Predictive value of topoisomerase IIalpha immunostaining in urothelial bladder carcinoma
###end article-title 67
###begin article-title 68
Comparison of topoisomerase II alpha and Ki-67 expression in uterine cervical squamous lesions
###end article-title 68
###begin article-title 69
Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle
###end article-title 69
###begin article-title 70
###xml 74 79 <span type="species:ncbi:9606">human</span>
Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies
###end article-title 70
###begin article-title 71
Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinoma
###end article-title 71
###begin article-title 72
Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases
###end article-title 72
###begin article-title 73
Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon
###end article-title 73
###begin article-title 74
###xml 144 152 <span type="species:ncbi:9606">patients</span>
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients
###end article-title 74
###begin article-title 75
Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas
###end article-title 75
###begin article-title 76
Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression
###end article-title 76
###begin article-title 77
###xml 118 125 <span type="species:ncbi:9606">patient</span>
Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival
###end article-title 77
###begin article-title 78
###xml 72 77 <span type="species:ncbi:9606">human</span>
Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types
###end article-title 78
###begin article-title 79
Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas
###end article-title 79
###begin article-title 80
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 64 69 <span type="species:ncbi:9606">human</span>
Human DNA topoisomerase I: an anticancer drug target present in human sarcomas
###end article-title 80
###begin article-title 81
Elevations of DNA topoisomerase I in invasive carcinoma of the breast
###end article-title 81
###begin article-title 82
Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas
###end article-title 82
###begin article-title 83
The significance of Epstein Barr Virus (EBV) & DNA topoisomerase IIu (DNA-TopoII) immunoreactivity in normal oral mucosa, oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC)
###end article-title 83
###begin article-title 84
Fluorinated pyrimidines: a new class of tumor inhibitory compounds
###end article-title 84
###begin article-title 85
Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy
###end article-title 85
###begin article-title 86
Markers of drug resistance in relapsing colon cancer
###end article-title 86
###begin article-title 87
Multidrug resistance proteins and topoisomerase II alpha expression in colon cancer: association with metastatic potential
###end article-title 87
###begin article-title 88
Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer
###end article-title 88
###begin article-title 89
Topoisomerase I (Topo-I) expression correlates to thymidylate synthase (TS) expression in colorectal cancer (CRC)
###end article-title 89
###begin article-title 90
Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin
###end article-title 90
###begin article-title 91
Clinical applications of anticancer drugs targeted to topoisomerase II
###end article-title 91
###begin article-title 92
Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I
###end article-title 92
###begin article-title 93
Continuing the fight against advanced colorectal cancer: new and future treatment options
###end article-title 93
###begin article-title 94
Topoisomerase II-drug interaction domains: identification of substituents on etoposide that interact with the enzyme
###end article-title 94
###begin article-title 95
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Prognostic value of neural invasion in rectal carcinoma: a multivariate analysis on 339 patients with curative resection
###end article-title 95
###begin article-title 96
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Irinotecan as second line therapy for patients with 5-FU refractory colorectal cancer
###end article-title 96
###begin article-title 97
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
###end article-title 97
###begin article-title 98
###xml 30 38 <span type="species:ncbi:9606">patients</span>
A phase II trial of CPT-11 in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group Study
###end article-title 98
###begin article-title 99
###xml 32 38 <span type="species:ncbi:9606">humans</span>
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea
###end article-title 99
###begin article-title 100
Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study
###end article-title 100
###begin article-title 101
###xml 136 144 <span type="species:ncbi:9606">patients</span>
A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma
###end article-title 101
###begin article-title 102
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study
###end article-title 102
###begin article-title 103
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination
###end article-title 103
###begin article-title 104
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer
###end article-title 104
###begin article-title 105
Cisplatin and etoposide in advanced colorectal carcinoma
###end article-title 105
###begin article-title 106
A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal cancer
###end article-title 106
###begin article-title 107
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Carboplatin and etoposide in previously treated colorectal cancer patients
###end article-title 107
###begin article-title 108
A phase I/II trial of 5-fluorouracil and etoposide in metastatic colorectal carcinoma
###end article-title 108
###begin article-title 109
Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis
###end article-title 109
###begin article-title 110
Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma
###end article-title 110
###begin article-title 111
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU + LV pre-treated patients with advanced colorectal cancer
###end article-title 111
###begin article-title 112
###xml 87 95 <span type="species:ncbi:9606">patients</span>
Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer
###end article-title 112
###begin p 113
An erratum to this article can be found at 
###end p 113

